GlassScriptPhysician profile
Andrew T Davies
NPI 1881918829
$7,907.23
in general payments reported to CMS, 2019-2025
32 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,317 · 2020: $671 · 2021: $1,535 · 2022: $1,539 · 2023: $1,141 · 2024: $913 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,108.16 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $992.53 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Lilly USA, LLC | $986.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $888.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $773.53 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Pfizer INC. | $501.46 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $420.07 | 2019-2023 | |
| Amgen INC. | $310.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $254.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.21 | 2020-2022 | |
| Noven Therapeutics, LLC | $170.74 | 2023-2025 | Xelstrym |
| Allergan, INC. | $157.23 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $153.79 | 2024 | Qelbree |
| Glaxosmithkline, LLC. | $120.08 | 2020-2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $104.59 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $100.03 | 2022 | |
| Esperion Therapeutics, INC. | $96.24 | 2021 | |
| Astellas Pharma US INC | $94.01 | 2022-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $85.36 | 2021 | |
| Shire North American Group INC | $65.62 | 2019 | |
| Exact Sciences Corporation | $58.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tris Pharma INC | $52.63 | 2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $39.03 | 2025 | Fanapt |
| Kerecis Limited | $31.65 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Abbott Laboratories | $23.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.02 | 2022 | |
| Currax Pharmaceuticals LLC | $21.78 | 2022 | |
| Amarin Pharma, INC. | $21.09 | 2020 | |
| Eisai INC. | $14.62 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.01 | 2023 | Trulance, Xifaxan |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.58 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Davies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.